Table 12 Expression levels of tumor-specific antigens in various cancer types
From: The use of RNA-based treatments in the field of cancer immunotherapy
Cancer Type | Antigen Name | Expression Level | Tissue Specificity | Frequency of Expression | Potential for Targeting with mRNA Vaccines | Reference |
|---|---|---|---|---|---|---|
Breast | HER2/neu | High | Breast | 20–30% | Yes | [671] |
Colorectal | CEA | High | Intestine | 70–80% | Yes | [672] |
Lung | EGFR | High | Lung | 10–20% | Yes | [673] |
Melanoma | MART-1 | High | Skin | 60–70% | Yes | [674] |
Ovarian | CA125 | High | Ovary | 80–90% | Yes | [675] |
Pancreatic | MUC1 | High | Pancreas | 90–100% | Yes | [676] |
Prostate | PSA | High | Prostate | 80–90% | Yes | [677] |
Renal | CAIX | High | Kidney | 85–95% | Yes | [678] |
Ovarian | NY-ESO-1 | Medium | Ovary | 10–15% | Yes | [679] |
Breast | MAGE-A1 | Medium | Breast | 15–20% | Yes | [44] |
Melanoma | gp100 | Medium | Skin | 30–40% | Yes | [680] |
Prostate | PSCA | Medium | Prostate | 20–30% | Yes | [681] |
Colorectal | MAGE-A3 | Low | Intestine | 5–10% | Yes | [682] |
Lung | NY-ESO-1 | Low | Lung | 5–10% | Yes | [683] |
Pancreatic | Survivin | Low | Pancreas | 5–10% | Yes | [684] |
Bladder | MAGE-A12 | Low | Bladder | 5–10% | Yes | [685] |
Brain | EGFRvIII | Low | Brain | 20–30% | Yes | [686] |
Breast | BRCA1 | Low | Breast | 10–15% | Yes | [687] |
Colorectal | TP53 | Low | Intestine | 15–20% | Yes | [688] |
Kidney | CD105 | Low | Kidney | 10–15% | Yes | [689] |
Liver | AFP | Low | Liver | 60–70% | Yes | [690] |
Lung | SLC34A2 | Low | Lung | 5–10% | Yes | [691] |
Ovarian | TP53 | Low | Ovary | 20–30% | Yes | [692] |
Pancreatic | KIF20A | Low | Pancreas | 10–15% | Yes | [693] |
Prostate | PSMA | Low | Prostate | 5–10% | Yes | [694] |
Sarcoma | NY-ESO-1 | Low | Bone and Soft Tissue | 5–10% | Yes | [695] |
Stomach | HER2/neu | Low | Stomach | 10–15% | Yes | [696] |
Thyroid | Thyroglobulin | Low | Thyroid | 80–90% | Yes | [697] |
Uterine | p16 | Low | Uterus | 15–20% | Yes | [698] |
Esophageal | MAGE-A4 | Low | Esophagus | 5–10% | Yes | [699] |
Head and Neck | p16 | Low | Head and Neck | 25–30% | Yes | [700] |
Leukemia | WT1 | Low | Blood | 75–85% | Yes | [701] |
Lymphoma | CD19 | Low | Lymphatic System | 100% | Yes | [702] |
Mesothelioma | Mesothelin | Low | Lungs | 70–80% | Yes | [703] |
Multiple Myeloma | NY-ESO-1 | Low | Blood | 20–30% | Yes | [704] |
Neuroblastoma | GD2 | Low | Nervous System | 95–100% | Yes | [705] |
Pancreatic | WT1 | Low | Pancreas | 10–15% | Yes | [706] |
Prostate | MUC1 | Low | Prostate | 5–10% | Yes | [707] |
Renal | WT1 | Low | Kidney | 15–20% | Yes | [708] |
Sarcoma | SSX2 | Low | Bone and Soft Tissue | 5–10% | Yes | [709] |
Stomach | MAGE-A3 | Low | Stomach | 10–15% | Yes | [710] |
Testicular | MAGE-A4 | Low | Testis | 5–10% | Yes | [711] |
Uterine | NY-ESO-1 | Low | Uterus | 5–10% | Yes | [698] |
Acute Myeloid Leukemia | PR1 | Medium | Blood | 60–70% | Yes | [712] |
Bladder | NY-ESO-1 | Medium | Bladder | 20–30% | Yes | [713] |
Brain | Survivin | Medium | Brain | 50–60% | Yes | [714] |
Breast | HER2/neu | Medium | Breast | 20–30% | Yes | [715] |
Colorectal | CEA | Medium | Intestine | 50–60% | Yes | [716] |
Kidney | Renin | Medium | Kidney | 50–60% | Yes | [717] |
Liver | Glypican-3 | Medium | Liver | 50–60% | Yes | [718] |
Lung | MUC1 | Medium | Lung | 50–60% | Yes | [719] |
Ovarian | MUC1 | Medium | Ovary | 50–60% | Yes | [720] |
Pancreatic | MUC1 | Medium | Pancreas | 50–60% | Yes | [721] |
Prostate | PSA | Medium | Prostate | 50–60% | Yes | [222] |
Sarcoma | MAGE-A4 | Medium | Bone and Soft Tissue | 20–30% | Yes | [722] |
Stomach | Survivin | Medium | Stomach | 50–60% | Yes | [723] |
Thyroid | Thyroid Peroxidase | Medium | Thyroid | 50–60% | Yes | [724] |